Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avigen, a biopharmaceutical company, has launched an exploratory study of the company's pipeline product, AV411, for the treatment of opioid withdrawal symptoms.
Subscribe to our email newsletter
The study is largely funded by the National Institute on Drug Abuse and will be run jointly by the New York State Psychiatric Institute and Columbia University.
The clinical study will assess the safety and tolerability of AV411, a non-opioid compound, when administered twice daily to heroin addicts who are maintained on morphine, a commonly used opiate analgesic drug, over a 14-day period. The trial will assess preliminary efficacy of AV411 for reducing the symptoms of opioid withdrawal.
Kenneth Chahine, president and CEO of Avigen, said: “This trial builds upon our research of AV411’s unique glial-attenuating properties and will complement Avigen’s clinical studies of AV411 to treat neuropathic pain. We believe both of these exploratory paths may show that AV411 can become a breakthrough therapy for these disabling disorders.”